Elekta
69.95 SEK +0.07%11 investors are following this company
Elekta provides medical technology. The company specializes in the development of clinical solutions for the treatment of cancer and brain diseases. Elekta's treatment system and planning software for radiation therapy and radiation surgery as well as other software systems are used in the healthcare industry to identify and analyze various health conditions. Operations are conducted on a global level, with headquarters in Stockholm.
Revenue
18.12B
EBIT %
11.25 %
P/E
20.51
Dividend yield-%
3.43 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
EKTA B
Daily low / high price
69.6 / 70.5
SEK
Market cap
26.83B SEK
Turnover
48.77M SEK
Volume
697K
Financial calendar
Interim report
27.11.2024
Interim report
21.02.2025
Annual report
28.05.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Fjärde AP-fonden | 9.1 % | 6.7 % |
Laurent Leksell fam och bolag | 5.7 % | 30.2 % |
T. Rowe Price | 4.5 % | 3.3 % |
Nordea funds | 3.8 % | 2.8 % |
SEB Funds | 3.6 % | 2.7 % |
Vanguard | 3.4 % | 2.5 % |
AMF Pension & Fonder | 3.2 % | 2.4 % |
Handelsbanken Fonder | 3.0 % | 2.2 % |
Lannebo Kapitalförvaltning AB | 3.0 % | 2.3 % |
Swedbank Robur Fonder | 2.6 % | 1.9 % |
ShowingAll content types
Elekta issues a SEK 1.5 billion bond and signs a revolving credit facility of SEK 1 billion
Elekta Evo submitted to U.S. FDA for premarket approval – to be featured at ASTRO
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools